A new study questions whether acetaminophen is a risk-free pain reliever for patients aged 65 and older, including those with osteoarthritis (OA). Although acetaminophen is often touted as an alternative to non-steroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen, a population-based cohort study found it carried an increased risk of peptic ulcers, bleeding and other side…
With the state legislative session in full swing, the ACR is currently tracking 114 pieces of state legislation across many issue areas, including utilization management, prescription drug review boards and vaccines.
With Mehmet Oz, MD, expected to be confirmed as administrator of the Centers for Medicare & Medicaid Services, the ACR considers how his stated priorities may affect rheumatology.
Three bills centering reintroduced in the 119th Congress would ease educational debt burden, increase placement access for visa holders and support the mental health of current healthcare workers.
Physicians have a lot going on. Between the pressures of clinical and administrative responsibilities, sometimes the only way to keep everything together is with a to-do list. Unfortunately, it can often feel as though some items never come off that list. Often, the bigger a project sounds, the more likely it is to sit on…
Here participants in the ACR’s Rheum With a (re)View program discuss how its mentors provided them with skills and knowledge that benefit their careers and rheumatology as a community.
Rheumatology workforce challenges are a global concern. Many challenges, especially the lack of trained rheumatology clinicians, are similar among countries and regions of the world, while others differ. The 2024 ACR Global Summit session on workforce featured a discussion by representatives of regional rheumatology organizations and the ACR addressing issues central to developing and retaining…
Inebilizumab reduces the risk of immunoglobulin G4-related disease (IgG4-RD) flares and increases the likelihood of flare-free, complete remission at one year, a recent study shows.1 The randomized, doubleblind, placebo-controlled MITIGATE trial showed that inebilizumab reduced the risk of IgG4-RD symptoms by 87%, compared with placebo. About IgG4-RD IgG4-RD is chronic, rare condition that has, so…
The transition from being a rheumatology fellow to being in private practice is significant. As I reflect on the past two years, I want to share my observations and begin a conversation about how to prepare rheumatology fellows for careers as practicing rheumatologists. The difference between learning about rheumatology and practicing rheumatology is nuanced. Upon…
My children were playing in the car the other day and pulled open the glove box. Inside, they found a brown paper bag with my last name “KUMAR” in black Sharpie and a red sticker that read, “Do not lose. No replacements available.” It wasn’t long before the kids tore that bag apart to find…